Q2 2024 Ajanta Pharma Ltd Earnings Call Transcript
Ajanta Pharma, Q2 FY 2024 earnings conference call. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. (Operator Instructions) Please note this conference is being recorded.
I now hand the conference over to Mr. Yogesh Agrawal, Managing Director of Ajanta Pharma Limited. Thank you, and over to you, sir.
Thank you. A very good evening and welcome to all of you. With me, I have Mr. Rajesh Agrawal, our Joint Managing Director; Mr. Arvind Agrawal, our CFO, Mr. Rajeev Agrawal, our AVP Finance and Investor Relations. So, friends I hope that the results are already there with you. We will take you through the business-wise performance for the Q2 and H1 for the year along with a comparison for the previous year same period.
So our three verticals of business Branded Generics, US Generics and Institution Business in Africa it generated the total revenue of INR1,028 crore against INR938 crore,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
